Efficacy of PD-L1 inhibitor avelumab in NEPC/AVPC

Dr. Brown (US) elaborates on the results of the study about the efficacy of the PD-L1 inhibitor avelumab in neuroendocrine or aggressive variant metastatic prostate cancer (NEPC/AVPC).